Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
957.00
+19.39 (+2.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
May 04, 2024
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments.
Via
InvestorPlace
Exposures
Product Safety
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
May 03, 2024
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
May 03, 2024
Via
Benzinga
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar
May 03, 2024
Discover three under-the-radar pharma stocks poised for significant growth in 2024. Explore their product pipelines and potential gains.
Via
InvestorPlace
Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology Industry
May 02, 2024
Via
Benzinga
Regeneron Earnings Miss; Biotech Giant's Stock Falls
May 02, 2024
The biotech giant's earnings and sales both missed Q1 estimates.
Via
Investor's Business Daily
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
April 30, 2024
Via
Benzinga
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
May 02, 2024
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.
Via
Benzinga
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
May 02, 2024
U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
May 02, 2024
REGN stock results show that Regeneron Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
April 18, 2024
Via
Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today
April 17, 2024
Via
Benzinga
Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views
April 12, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
May 02, 2024
Via
Benzinga
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 02, 2024
It pays to develop novel medicines for life-threatening illnesses.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
April 30, 2024
Via
Benzinga
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
April 25, 2024
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.
Via
Benzinga
2 Small-Cap Growth Stocks With Room To Run
April 24, 2024
These two small-cap growth stocks could be ready to run.
Via
The Motley Fool
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
April 11, 2024
Via
Benzinga
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
March 28, 2024
Via
Benzinga
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
March 26, 2024
Via
Benzinga
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...
Via
Benzinga
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
April 12, 2024
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
April 11, 2024
The U.S. Justice Department accuses Regeneron Pharmaceuticals of Medicare fraud related to its macular degeneration drug, Eylea. Allegations include manipulating drug prices, resulting in inflated...
Via
Benzinga
Topics
Fraud
Exposures
Legal
Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?
April 11, 2024
Regeneron has fallen more than 6% over the past six weeks, and dropped again Thursday, as the DOJ focuses on its Eylea franchise.
Via
Investor's Business Daily
Should You Sell This Stock Following a Regulatory Roadblock?
April 05, 2024
It's not the first such obstacle this high-performing drugmaker has faced.
Via
The Motley Fool
5 Healthcare Stocks to Buy for 2024
April 02, 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
April 01, 2024
Via
Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
March 28, 2024
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.